News | December 28, 2025
Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This recognition demonstrate excellence in intellectual property (IP) value creation.
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Subscribe To Our Newsletter & Stay Updated
